Eikon Therapeutics develops cancer medicines, with its most advanced candidate in Phase 2/3 trials for melanoma. EIKN reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 16 | HC Wainwright & Co. | Initiated | Buy | |
| Aug 14 | Wedbush | Maintained | Sell |
Whale Options Flow
90DNo whale options trades in EIKN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EIKN is in one of them and how their past EIKN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EIKN in an article yet. Here's the latest on the wider market.
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company based in Millbrae, California, that is developing medicines for cancer. Its main focus is oncology, and its most advanced candidate, EIK1001, is in Phase 2/3 trials with pembrolizumab for advanced melanoma. The company also has candidates that inhibit PARP1 for ovarian, breast, prostate and pancreatic cancers, plus an early-stage helicase inhibitor. Its medicines are still in clinical development and are not yet sold to patients.
- Headquarters
- Millbrae, CA